Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

CI

Cigna Stock in Brief

A strong performer from today's afternoon trading session is Cigna, whose shares rose 2.4% to $306.35 per share. For those of you thinking about investing in the stock, here is a brief value analysis of the stock using the company's basic fundamental ratios.

a Lower P/B Ratio Than Its Sector Average but Trading Above Its Fair Price:

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. The company belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) ratio of 3.19. In contrast, Cigna has a trailing 12 month P/E ratio of 16.8 and a P/B ratio of 2.03.

Cigna has moved -6.5% over the last year compared to 13.8% for the S&P 500 — a difference of -20.4%. Cigna has a 52 week high of $350.0 and a 52 week low of $256.89.

Generally Positive Cash Flows but Not Enough Current Assets to Cover Current Liabilities:

2019 2020 2021 2022 2023 2024
Revenue (M) $153,566 $160,401 $174,069 $180,518 $195,265 $247,121
Operating Margins 5% 5% 5% 5% 4% 4%
Net Margins 3% 5% 3% 4% 3% 2%
Net Income (M) $5,120 $8,489 $5,420 $6,782 $5,372 $3,778
Net Interest Expense (M) $1,600 -$1,438 -$1,208 -$1,228 -$1,446 $1,500
Depreciation & Amort. (M) $3,651 $2,802 $2,923 $2,937 $3,035 $2,775
Diluted Shares (M) 380 368 341 313 297 283
Earnings Per Share $13.44 $22.96 $15.75 $21.41 $17.39 $12.12
EPS Growth n/a 70.83% -31.4% 35.94% -18.78% -30.3%
Avg. Price $164.0 $180.93 $217.69 $241.67 $299.45 $299.27
P/E Ratio 12.08 7.81 13.7 11.16 17.04 24.43
Free Cash Flow (M) $8,435 $9,256 $7,191 $8,656 $11,813 $10,363
EV / EBITDA 8.11 8.16 9.68 9.02 9.68 9.18
Total Debt (M) $37,407 $32,919 $33,670 $31,093 $30,930 $31,972
Net Debt / EBITDA 2.8 2.08 2.63 2.21 2.0 2.0
Current Ratio 0.74 0.77 0.83 0.73 0.77 0.84
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS